MX370442B - Proteínas quiméricas de una lisina de bacteriófago de streptococcus para la detección y tratamiento de bacterias gram positivas. - Google Patents

Proteínas quiméricas de una lisina de bacteriófago de streptococcus para la detección y tratamiento de bacterias gram positivas.

Info

Publication number
MX370442B
MX370442B MX2016000588A MX2016000588A MX370442B MX 370442 B MX370442 B MX 370442B MX 2016000588 A MX2016000588 A MX 2016000588A MX 2016000588 A MX2016000588 A MX 2016000588A MX 370442 B MX370442 B MX 370442B
Authority
MX
Mexico
Prior art keywords
treatment
positive bacteria
detection
gram positive
streptococcus
Prior art date
Application number
MX2016000588A
Other languages
English (en)
Inventor
Vincent A Fischetti
Jonathan Schmitz
Daniel Gilmer
Chad Euler
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Publication of MX370442B publication Critical patent/MX370442B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a proteínas quimérica y métodos y composiciones de las mismas útiles para el mejoramiento terapéutico y tratamiento de bacterias gram positivas, que incluyen Streptococcus y Staphylococcus, y afecciones relacionadas. La presente provee composiciones y métodos que incorporan y utilizan proteínas quiméricas de lisinas de bacteriófago derivadas de Streptococcus suis, particularmente la enzima lítica PlySs2, y variantes de la misma que incluyen porciones biológicamente activas de las mismas. Se provee el uso de composiciones que comprenden proteínas quiméricas en la preparación de un medicamento para la destrucción de bacterias, que incluyen Streptococcus y Staphylococcus, y el tratamiento de una infección bacteriana gram positiva en humanos.
MX2016000588A 2011-04-21 2012-04-20 Proteínas quiméricas de una lisina de bacteriófago de streptococcus para la detección y tratamiento de bacterias gram positivas. MX370442B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161477836P 2011-04-21 2011-04-21
PCT/US2012/034456 WO2012145630A2 (en) 2011-04-21 2012-04-20 Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria

Publications (1)

Publication Number Publication Date
MX370442B true MX370442B (es) 2019-12-13

Family

ID=47042182

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2013012241A MX336427B (es) 2011-04-21 2012-04-20 Lisinas de bacteriofago de estreptococcus para la deteccion y tratamiento de bacterias gram positivas.
MX2016000588A MX370442B (es) 2011-04-21 2012-04-20 Proteínas quiméricas de una lisina de bacteriófago de streptococcus para la detección y tratamiento de bacterias gram positivas.
MX2021007008A MX2021007008A (es) 2011-04-21 2013-10-18 Lisinas de bacteriófago de streptococcus para la detección y tratamiento de bacterias gram positivas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013012241A MX336427B (es) 2011-04-21 2012-04-20 Lisinas de bacteriofago de estreptococcus para la deteccion y tratamiento de bacterias gram positivas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021007008A MX2021007008A (es) 2011-04-21 2013-10-18 Lisinas de bacteriófago de streptococcus para la detección y tratamiento de bacterias gram positivas.

Country Status (12)

Country Link
US (7) US9034322B2 (es)
EP (2) EP2699253B1 (es)
JP (4) JP6139509B2 (es)
CN (4) CN108578685A (es)
AU (3) AU2012245357B2 (es)
CA (1) CA2833409A1 (es)
DK (1) DK2699253T3 (es)
ES (1) ES2682670T3 (es)
HK (2) HK1244503A1 (es)
IL (4) IL228869B (es)
MX (3) MX336427B (es)
WO (1) WO2012145630A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3604339T3 (pl) 2011-01-14 2021-12-27 The Regents Of The University Of California Terapeutyczne przeciwciała przeciwko białku ror-1 i sposoby ich zastosowania
US20140179594A1 (en) * 2011-04-21 2014-06-26 The Rockefeller University Streptococcus bacteriophage lysins for treatment of gram positive bacteria in companion animals and livestock
NL2007038C2 (en) * 2011-07-04 2013-01-07 Vereniging Voor Christelijk Hoger Onderwijs System and method for predicting the viability of a body tissue in a patient, and measuring device used therein.
US10813983B2 (en) * 2012-05-09 2020-10-27 Contrafect Corporation Bacteriophage lysin and antibiotic combinations against gram positive bacteria
US9499594B2 (en) * 2012-05-09 2016-11-22 Contrafect Corporation Biofilm prevention, disruption and treatment with bacteriophage lysin
CN104073478A (zh) * 2014-06-13 2014-10-01 上海交通大学 杀灭革兰氏阳性菌的酶抗生素及其制备、用途
KR102441211B1 (ko) * 2014-06-26 2022-09-07 더 락커펠러 유니버시티 아시네토박터 라이신
CN104726439B (zh) * 2015-04-13 2017-11-14 武汉菲吉乐科生物科技有限公司 一种广谱的链球菌裂解酶及其应用
CN104805066B (zh) * 2015-05-18 2018-04-24 武汉菲吉乐科生物科技有限公司 一种葡萄球菌裂解酶及其应用
WO2017023680A1 (en) * 2015-07-31 2017-02-09 The Regents Of The University Of California Mycobacterium lysterase: a novel treatment for acne
US20180353575A1 (en) * 2015-09-13 2018-12-13 The Rockefeller University Clostridium difficile bacteriophage lysins for detection and treatment of clostridium difficile bacteria infection
AU2016324298B2 (en) 2015-09-17 2022-09-01 Contrafect Corporation Lysin polypeptides active against Gram-negative bacteria
AU2017263563A1 (en) 2016-05-12 2018-10-18 Contrafect Corporation Broth microdilution method for evaluating and determining minimal inhibitory concentration of antibacterial polypeptides
MX2020000018A (es) * 2017-07-10 2020-10-01 Contrafect Corp Potencializacion de componentes sanguineos de actividad anti-bacteriana de proteina litica y metodos y usos de estos.
EP3735268A4 (en) * 2018-01-05 2021-12-22 Azitra, Inc. AUXOTROPHIC STRAINS OF STAPHYLOCOCCUS BACTERIA
EP3758738A4 (en) * 2018-02-26 2021-12-08 Contrafect Corporation MODIFIED PLYSS2-LYSINE AND USES THEREOF
KR102073088B1 (ko) * 2018-06-04 2020-02-04 (주)인트론바이오테크놀로지 신규한 스트렙토코커스 수이스 박테리오파지 Str-SUP-2 및 이의 스트렙토코커스 수이스 균 증식 억제 용도
KR102073094B1 (ko) * 2018-06-04 2020-02-04 (주)인트론바이오테크놀로지 신규한 스트렙토코커스 수이스 박테리오파지 Str-SUP-3 및 이의 스트렙토코커스 수이스 균 증식 억제 용도
KR102073086B1 (ko) * 2018-06-04 2020-02-04 (주)인트론바이오테크놀로지 신규한 스트렙토코커스 수이스 박테리오파지 Str-SUP-1 및 이의 스트렙토코커스 수이스 균 증식 억제 용도
WO2020037031A1 (en) * 2018-08-17 2020-02-20 Becton, Dickinson And Company Antimicrobial susceptibility testing using microdroplets
WO2020077286A1 (en) 2018-10-12 2020-04-16 Quidel Corporation Extraction reagent for use in an assay for detection of group a streptococcus
JP2022525914A (ja) * 2019-03-22 2022-05-20 コントラフェクト コーポレイション 感染性心内膜炎を治療する方法
MX2021012166A (es) * 2019-04-05 2021-11-03 Contrafect Corp Lisinas y sus derivados con actividad bactericida contra pseudomona aeruginosa, en la presencia de suero humano.
MX2021012375A (es) * 2019-04-11 2021-11-17 Contrafect Corp Metodo para tratar y prevenir infecciones oseas y de articulaciones.
CA3178761A1 (en) * 2020-05-19 2021-11-25 Raymond Schuch Modified plyss2 lysins and antibiotic combinations for use against gram-positive bacteria
US20220087266A1 (en) * 2020-09-22 2022-03-24 Mars, Incorporated Compositions and methods for controlling mycotoxin production
CN114480299B (zh) * 2020-10-27 2023-08-29 暨南大学 一种蜡样芽胞杆菌噬菌体及其应用
CN112760312B (zh) * 2021-01-20 2022-06-17 华中农业大学 一种裂解革兰氏阳性菌的裂解酶plyssX609及其应用
WO2023049747A1 (en) * 2021-09-22 2023-03-30 Elanco Us Inc. Streptococcus suis lytic enzyme compositions and methods of use thereof
KR20240015755A (ko) * 2022-07-26 2024-02-06 주식회사 인트론바이오테크놀로지 연쇄상구균에 대하여 용균 활성을 갖는 항균단백질
WO2024059184A1 (en) * 2022-09-16 2024-03-21 The Johns Hopkins University Machine learning systems and related aspects for the detection of disease states
CN116640754B (zh) * 2023-07-21 2023-10-10 临沂大学 一种链球菌前噬菌体裂解酶lys224及应用
CN117051043B (zh) * 2023-10-11 2024-01-30 圆因(北京)生物科技有限公司 一种基于环状rna编码耐甲氧西林金黄色葡萄球菌内溶素及其应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278378A (en) 1962-04-19 1966-10-11 Schindler Charles Alvin Staphylococcus-derived antibiotic
US3398056A (en) 1964-07-10 1968-08-20 Mead Johnson & Co Process for producing lysostaphin by fermentation
US3594284A (en) 1968-06-04 1971-07-20 Mead Johnson & Co Lysostaphin fermentation with accelerated time cycle
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1985002092A1 (en) 1983-11-14 1985-05-23 Bio-Mimetics Inc. Bioadhesive compositions and methods of treatment therewith
GB2183661B (en) 1985-03-30 1989-06-28 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
EP0285649A4 (en) 1986-10-08 1990-06-27 David Bernstein METHOD FOR EXPOSING ANTIGENS OF GROUP A STREPTOCOCCUS AND IMPROVED DIAGNOSTIC TEST FOR THE IDENTIFICATION OF GROUP A STREPTOCOCCUS
US4948580A (en) 1988-12-08 1990-08-14 E. R. Squibb & Sons, Inc. Muco-bioadhesive composition
JPH02258718A (ja) 1989-03-31 1990-10-19 Nippon Kayaku Co Ltd ペースト状基剤及び製剤
US5264563A (en) 1990-08-24 1993-11-23 Ixsys Inc. Process for synthesizing oligonucleotides with random codons
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5554380A (en) 1994-08-04 1996-09-10 Kv Pharmaceutical Company Bioadhesive pharmaceutical delivery system
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
US5942243A (en) 1996-11-12 1999-08-24 Polytherapeutics, Inc. Mucoadhesive compositions for administration of biologically active agents to animal tissue
US6248324B1 (en) 1997-10-31 2001-06-19 Vincent Fischetti Bacterial phage associated lysing enzymes for treating dermatological infections
US6254866B1 (en) 1997-10-31 2001-07-03 New Horizons Diagnostics Corporation Use of phage associated lytic enzymes for treating bacterial infections of the digestive tract
US5997862A (en) 1997-10-31 1999-12-07 New Horizons Diagnostics Corporation Therapeutic treatment of group A streptococcal infections
US20060292135A1 (en) * 1997-10-31 2006-12-28 Lawrence Loomis Use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl
US6264945B1 (en) 1997-10-31 2001-07-24 Vincent A Fischetti Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
JP2002537350A (ja) 1999-02-25 2002-11-05 ニュー ホライズンズ ダイアグノスティックス インコーポレーティッド 連鎖球菌感染の予防的及び治療的な処置のための手段
CN1352567A (zh) * 1999-02-25 2002-06-05 新眼界诊断公司 预防性和治疗性治疗链球菌感染的方法
US6056955A (en) 1999-09-14 2000-05-02 Fischetti; Vincent Topical treatment of streptococcal infections
EP1501925A4 (en) 2002-05-17 2006-10-25 New Horizons Diagnostics Corp IDENTIFICATION OF A PHAGEN-ASSOCIATED LYTICAL ENZYME FOR THE FAST AND SPECIFIC DETECTION AND BUTTERFLY OF BACILLUS ANTHRACIS
US8326388B2 (en) 2002-10-31 2012-12-04 Toshiba Medical Systems Corporation Method and apparatus for non-invasive measurement of living body characteristics by photoacoustics
JP2006506989A (ja) * 2002-11-07 2006-03-02 シナジー アメリカ，インコーポレイテッド 肺炎球菌感染を治療または予防するための組成物および方法
US7582729B2 (en) 2003-05-15 2009-09-01 The Rockefeller University Nucleic acids and polypeptides of C1 bacteriophage and uses thereof
US7569223B2 (en) 2004-03-22 2009-08-04 The Rockefeller University Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions
US7638600B2 (en) 2004-03-24 2009-12-29 The Rockefeller University Lytic enzymes and spore surface antigen for detection and treatment of Bacillus anthracis bacteria and spores
GB0410220D0 (en) * 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
WO2008018854A2 (en) 2005-06-06 2008-02-14 The Rockefeller University Bactiophage lysins for bacillus anthracis
US7582291B2 (en) * 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
DE602006018746D1 (de) * 2005-08-24 2011-01-20 Univ Rockefeller Ply-gbs-lysinmutanten
IE20060488A1 (en) * 2006-06-29 2008-01-09 Teagasc Agric Food Dev Authori Recombinant staphylococcal phage lysin as an antibacterial agent
DE102006061002A1 (de) * 2006-12-22 2008-06-26 Profos Ag Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von gram-positiven Bakterien
JP2011504366A (ja) 2007-11-26 2011-02-10 プラント バイオサイエンス リミティド エンドリシン活性を有する新規ポリペプチド及びその使用
EP2103308A1 (de) * 2008-03-20 2009-09-23 PhytoLine GmbH Verfahren zur Herstellung eines Gemisches von Bakteriophagen und deren Verwendung für die Therapie von Antibiotika-resistenten Staphylococcen
EP3263588A1 (en) 2008-07-03 2018-01-03 The Rockefeller University Isolated staphylococcus-specific soluble binding molecule
CA2736062A1 (en) * 2008-07-24 2010-01-28 The United State Of America, As Represented By The Secretary Of Agricuure Triple acting antimicrobials that are refractory to resistance development
GB0815484D0 (en) * 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
KR101016918B1 (ko) * 2009-01-08 2011-02-25 주식회사 인트론바이오테크놀로지 박테리아 특이적 넓은 항균 활성을 갖는 신규한 리신 단백질
WO2011091412A1 (en) * 2010-01-25 2011-07-28 Alere Scarborough, Inc. A25 bacteriophage lysin
US20140179594A1 (en) * 2011-04-21 2014-06-26 The Rockefeller University Streptococcus bacteriophage lysins for treatment of gram positive bacteria in companion animals and livestock

Also Published As

Publication number Publication date
AU2017202728A1 (en) 2017-05-18
US11111484B2 (en) 2021-09-07
JP2019022504A (ja) 2019-02-14
IL287530A (en) 2021-12-01
JP6735796B2 (ja) 2020-08-05
EP2699253B1 (en) 2018-03-28
US20200002694A1 (en) 2020-01-02
AU2017202728B2 (en) 2019-04-04
US20200149025A1 (en) 2020-05-14
WO2012145630A3 (en) 2014-05-01
HK1244503A1 (zh) 2018-08-10
JP2016147903A (ja) 2016-08-18
IL271300A (en) 2020-01-30
JP2017171686A (ja) 2017-09-28
CN115887627A (zh) 2023-04-04
WO2012145630A2 (en) 2012-10-26
JP6139509B2 (ja) 2017-05-31
CA2833409A1 (en) 2012-10-26
CN107189997A (zh) 2017-09-22
EP2699253A4 (en) 2015-07-01
US9034322B2 (en) 2015-05-19
US20140072549A1 (en) 2014-03-13
US20230167427A9 (en) 2023-06-01
AU2012245357A1 (en) 2013-11-14
NZ731111A (en) 2019-06-28
JP6284976B2 (ja) 2018-02-28
IL266476B (en) 2020-01-30
CN103857410A (zh) 2014-06-11
CN108578685A (zh) 2018-09-28
MX2021007008A (es) 2022-06-02
NZ616945A (en) 2015-11-27
MX336427B (es) 2016-01-18
AU2019204660A1 (en) 2019-07-18
EP2699253A2 (en) 2014-02-26
IL266476A (en) 2019-06-30
IL228869B (en) 2019-05-30
US20170298334A1 (en) 2017-10-19
US20220127590A1 (en) 2022-04-28
AU2012245357B2 (en) 2017-06-08
ES2682670T3 (es) 2018-09-21
US20150267185A1 (en) 2015-09-24
DK2699253T3 (en) 2018-07-16
US9914915B2 (en) 2018-03-13
IL271300B (en) 2021-12-01
US20220064615A1 (en) 2022-03-03
US11155799B2 (en) 2021-10-26
HK1247956A1 (zh) 2018-10-05
IL228869A0 (en) 2013-12-31
AU2019204660B2 (en) 2021-01-28
JP6587655B2 (ja) 2019-10-09
MX2013012241A (es) 2014-05-07
EP3252155A1 (en) 2017-12-06
JP2014518849A (ja) 2014-08-07
US10544407B2 (en) 2020-01-28
NZ713076A (en) 2017-05-26

Similar Documents

Publication Publication Date Title
MX2021007008A (es) Lisinas de bacteriófago de streptococcus para la detección y tratamiento de bacterias gram positivas.
IL274832A (en) Combinations of bacteriophage lysine and antibiotics against gram-positive bacteria
WO2013122888A3 (en) Methods of treating bacterial infections
BR112012033212A2 (pt) uso de lactobacillo inibindo a produção de gás de bactéria coliforme isolada em infantes afetados por cólica
WO2014018596A3 (en) Alpha (1,2) fucosyltransferases suitable for use in the production of fucosylated oligosaccharides
WO2013184755A3 (en) Seca inhibitors and methods of making and using thereof
HK1207002A1 (en) Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections
GB201013307D0 (en) Anti-microbial metal organic framework
MX2013006873A (es) Una composicion que comprende un agente antibiotico y un agente dispersante o un agente antiadhesivo.
WO2013036783A3 (en) Methods for treating intrapulmonary infections
PH12014502680A1 (en) Polysaccharide compositions and methods of use
WO2013166282A3 (en) Methods and compositions for treating bacterial infection
PH12015501131A1 (en) Fibrinolytic compositions comprising bromelain and nattokinase for the prevention and treatment of phlebothrombotic states
AU2012335397A8 (en) Novel bacteriophages
WO2012141540A3 (ko) 바이러스 감염 억제 활성을 갖는 신규 분리한 락토바실러스 퍼멘텀 균주
WO2013009678A3 (en) Compositions and methods for the treatment of norovirus infection
WO2013155320A3 (en) Use of microbial gene products to prevent or treat microbial infections
WO2015063608A3 (en) Prevention and dispersion of biolfilm
PL391552A1 (pl) Nowe szczepy bakteriofagów do leczenia zakażeń bakteryjnych, zwłaszcza szczepami bakterii lekoopornych rodzaju Stenotrophomonas
PL392681A1 (pl) Nowe szczepy bakteriofagów do leczenia zakażeń bakteryjnych, zwłaszcza szczepami bakterii lekoopornych z rodzaju Klebsiella
IN2014KN02584A (es)
MX2013012603A (es) Vancomicina liposomal para el tratamiento de infecciones por estafilococo aureus resistente a la meticilina (sarm).
MY182136A (en) Pharmaceutical compositions